Markets:

Overview

News

Currencies

International

Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

1.420 +0.150 (+11.81%)

Streaming Delayed Price Updated: 3:04 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Why Is Mainz Biomed (MYNZ) Stock Moving Today? ↗

November 01, 2023

Mainz Biomed stock is on the move Wednesday as investors in MYNZ react to results from a colorectal cancer screening test campaign.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 01, 2023

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today!

Via InvestorPlace

Today's Pharma Tales Of Loss And Success: Pfizer Swings To A Quarterly Loss And Mainz Biomed Reports Positive Interim Screening Campaign Results ↗

October 31, 2023

As it struggles to navigate the rapid decline of its Covid-19 fame, Pfizer Inc (NYSE: PFE) reported a quarterly loss for the third quarter.

Via Benzinga

Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper

October 31, 2023

Almost half of Zöller-KipperGmbH’s employees in Germany participated in the screening program so far using ColoAlert®, Mainz Biomed’s user-friendly, at-home colorectal cancer (CRC) screening test

From Mainz BioMed NV

Via GlobeNewswire

What 5 Analyst Ratings Have To Say About Mainz Biomed ↗

September 26, 2023

Via Benzinga

Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations

October 26, 2023

From Mainz BioMed NV

Via GlobeNewswire

Mainz Biomed Presents Groundbreaking Results of ColoFuture Study

October 18, 2023

From Mainz BioMed NV

Via GlobeNewswire

Johnson & Johnson Was Saved By Its Focus On MedTech And Innovative Medicine ↗

October 17, 2023

Johnson & Johnson (NYSE: JNJ) reported its third quarter results that topped Wall Street’s expectations while also lifting its full year guidance fueled by a strong performance of its pharmaceutical...

Via Benzinga

Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark

October 11, 2023

Mainz Biomed team members will be available throughout the event at the Company’s booth located in Hall C, Stand C3-92

From Mainz BioMed NV

Via GlobeNewswire

Big Pharma Could Transform Into BioTech Pharma ↗

October 10, 2023

As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall...

Via Benzinga

Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit

October 05, 2023

From Mainz BioMed NV

Via GlobeNewswire

Mainz Biomed Continues To Transform Early Cancer Detection Across The Globe ↗

October 04, 2023

While Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) are making great progress in cancer treatments, the importance of early detection in combating this disease cannot be overstated.

Via Benzinga

Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania

October 04, 2023

Strategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian Population

From Mainz BioMed NV

Via GlobeNewswire

Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize Medicine ↗

September 27, 2023

Pharma companies across the globe, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), are harnessing the potential of mRNA which is creating plenty of space for scientific improvement in...

Via Benzinga

Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology

September 27, 2023

From Mainz BioMed NV

Via GlobeNewswire

AI To Revolutionize Clinical Trials And Diagnostics ↗

September 22, 2023

With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving...

Via Benzinga

Topics Artificial Intelligence

Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference

September 20, 2023

From Mainz BioMed NV

Via GlobeNewswire

Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

September 13, 2023

Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of...

Via Benzinga

Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention ↗

September 13, 2023

By the words of Dr. Ruediger Dahlke, cancer is a caricature of today’s modern society as it reflects the dark side ‘growth’. Our civilization is clearly more on the dark side of growth with technology...

Via Benzinga

Why Mainz Biomed Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket ↗

September 13, 2023

Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares rose 38.7% to $0.1713 in pre-market trading. Shares of Avalo Therapeutics jumped over 45% on Tuesday after the company agreed to divest AVTX-800...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

September 13, 2023

It's time for another dive into the biggest pre-market stock movers as we check out all the shares worth watching on Wednesday!

Via InvestorPlace

Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%

September 13, 2023

From Mainz BioMed NV

Via GlobeNewswire

10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar

September 06, 2023

--News Direct--

Via News Direct

Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle ↗

September 05, 2023

Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries'...

Via Benzinga

10 Reasons You May Want To Have Mainz Biomed (NASDAQ: MYNZ) On Your Radar ↗

September 05, 2023

The WHO reports that colorectal cancer is the second most fatal cancer around the world.

Via Benzinga

Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market

September 05, 2023

From Mainz BioMed NV

Via GlobeNewswire

Second Most Fatal Cancer In U.S. May Face A Big Fight From Mainz Biomed’s Non-Invasive Test; (NASDAQ: MYNZ) Is Making Early Detection Possible

August 30, 2023

--News Direct--

Via News Direct

Second Most Fatal Cancer In U.S. May Soon Face A Challenger: Mainz Biomed's (NASDAQ: MYNZ) Early Detection Tech ↗

August 29, 2023

Colorectal cancer is the third most common cancer worldwide, and although the majority of colorectal cancer cases have historically occurred in individuals aged 45 and older, it is increasingly...

Via Benzinga

Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference

August 29, 2023

Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4

From Mainz BioMed NV

Via GlobeNewswire

Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland

August 22, 2023

Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland

From Mainz BioMed NV

Via GlobeNewswire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.